These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 35714601)

  • 1. Structures of an active type III-A CRISPR effector complex.
    Smith EM; Ferrell S; Tokars VL; Mondragón A
    Structure; 2022 Aug; 30(8):1109-1128.e6. PubMed ID: 35714601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of cyclic oligoadenylate synthesis by the
    Nasef M; Muffly MC; Beckman AB; Rowe SJ; Walker FC; Hatoum-Aslan A; Dunkle JA
    RNA; 2019 Aug; 25(8):948-962. PubMed ID: 31076459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural organization of a Type III-A CRISPR effector subcomplex determined by X-ray crystallography and cryo-EM.
    Dorsey BW; Huang L; Mondragón A
    Nucleic Acids Res; 2019 Apr; 47(7):3765-3783. PubMed ID: 30759237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystal Structures of Csm2 and Csm3 in the Type III-A CRISPR-Cas Effector Complex.
    Takeshita D; Sato M; Inanaga H; Numata T
    J Mol Biol; 2019 Feb; 431(4):748-763. PubMed ID: 30639408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular determinants for CRISPR RNA maturation in the Cas10-Csm complex and roles for non-Cas nucleases.
    Walker FC; Chou-Zheng L; Dunkle JA; Hatoum-Aslan A
    Nucleic Acids Res; 2017 Feb; 45(4):2112-2123. PubMed ID: 28204542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The structure of a Type III-A CRISPR-Cas effector complex reveals conserved and idiosyncratic contacts to target RNA and crRNA among Type III-A systems.
    Paraan M; Nasef M; Chou-Zheng L; Khweis SA; Schoeffler AJ; Hatoum-Aslan A; Stagg SM; Dunkle JA
    PLoS One; 2023; 18(6):e0287461. PubMed ID: 37352230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamics of Cas10 Govern Discrimination between Self and Non-self in Type III CRISPR-Cas Immunity.
    Wang L; Mo CY; Wasserman MR; Rostøl JT; Marraffini LA; Liu S
    Mol Cell; 2019 Jan; 73(2):278-290.e4. PubMed ID: 30503774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coupling of ssRNA cleavage with DNase activity in type III-A CRISPR-Csm revealed by cryo-EM and biochemistry.
    Guo M; Zhang K; Zhu Y; Pintilie GD; Guan X; Li S; Schmid MF; Ma Z; Chiu W; Huang Z
    Cell Res; 2019 Apr; 29(4):305-312. PubMed ID: 30814678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-transcriptional DNA and RNA Cleavage during Type III CRISPR-Cas Immunity.
    Samai P; Pyenson N; Jiang W; Goldberg GW; Hatoum-Aslan A; Marraffini LA
    Cell; 2015 May; 161(5):1164-1174. PubMed ID: 25959775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type III CRISPR-Cas: beyond the Cas10 effector complex.
    Stella G; Marraffini L
    Trends Biochem Sci; 2024 Jan; 49(1):28-37. PubMed ID: 37949766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type III CRISPR-Cas Immunity: Major Differences Brushed Aside.
    Tamulaitis G; Venclovas Č; Siksnys V
    Trends Microbiol; 2017 Jan; 25(1):49-61. PubMed ID: 27773522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tetramerisation of the CRISPR ring nuclease Crn3/Csx3 facilitates cyclic oligoadenylate cleavage.
    Athukoralage JS; McQuarrie S; Grüschow S; Graham S; Gloster TM; White MF
    Elife; 2020 Jun; 9():. PubMed ID: 32597755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystal structure of the Cmr2-Cmr3 subcomplex in the CRISPR-Cas RNA silencing effector complex.
    Osawa T; Inanaga H; Numata T
    J Mol Biol; 2013 Oct; 425(20):3811-23. PubMed ID: 23583914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystal structure of the CRISPR-Cas RNA silencing Cmr complex bound to a target analog.
    Osawa T; Inanaga H; Sato C; Numata T
    Mol Cell; 2015 May; 58(3):418-30. PubMed ID: 25921071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary processing of CRISPR RNA by the endonuclease Cas6 in Staphylococcus epidermidis.
    Wakefield N; Rajan R; Sontheimer EJ
    FEBS Lett; 2015 Oct; 589(20 Pt B):3197-204. PubMed ID: 26364721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ribonuclease activity of Csm6 is required for anti-plasmid immunity by Type III-A CRISPR-Cas systems.
    Foster K; Kalter J; Woodside W; Terns RM; Terns MP
    RNA Biol; 2019 Apr; 16(4):449-460. PubMed ID: 29995577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structures of the Cmr-β Complex Reveal the Regulation of the Immunity Mechanism of Type III-B CRISPR-Cas.
    Sofos N; Feng M; Stella S; Pape T; Fuglsang A; Lin J; Huang Q; Li Y; She Q; Montoya G
    Mol Cell; 2020 Sep; 79(5):741-757.e7. PubMed ID: 32730741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type III-A CRISPR-Cas Csm Complexes: Assembly, Periodic RNA Cleavage, DNase Activity Regulation, and Autoimmunity.
    Jia N; Mo CY; Wang C; Eng ET; Marraffini LA; Patel DJ
    Mol Cell; 2019 Jan; 73(2):264-277.e5. PubMed ID: 30503773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Target RNA capture and cleavage by the Cmr type III-B CRISPR-Cas effector complex.
    Hale CR; Cocozaki A; Li H; Terns RM; Terns MP
    Genes Dev; 2014 Nov; 28(21):2432-43. PubMed ID: 25367038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure Studies of the CRISPR-Csm Complex Reveal Mechanism of Co-transcriptional Interference.
    You L; Ma J; Wang J; Artamonova D; Wang M; Liu L; Xiang H; Severinov K; Zhang X; Wang Y
    Cell; 2019 Jan; 176(1-2):239-253.e16. PubMed ID: 30503210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.